SGS Life Sciences will roll out new biologics testing capabilities across its network in bid to be the world’s number one contract biopharmaceuticals testing laboratory by 2014.
A strategic partnership between New England IRB (NEIRB) and Veritas IRB of Montreal will see their clients following a common protocol review for studies they conduct throughout the US and Canada.
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
The FDA is to collaborate with the WHO to build a global surveillance and monitoring system for combating falsified medicines and breaches of the supply chain.
IMS Health predicts that global drug sales will increase 5 to 7 per cent next year, driven by development of innovative pharmaceuticals and growth of emerging markets.
Easily translatable and adaptable simplified clinical research ethic training guidelines have been created to support field workers in low-resource settings.
Guy Villax, board member of the EFCG, talks falsified APIs, EU efforts to tackle the issue, and the presence of gangsters in the pharma industry in an in-PharmaTechnologist video interview.
Wipro Technologies has introduced Rapid Trials to provide clients with a data collection platform that can be deployed quickly and with minimal infrastructure investment.
China leads the field in 'potential future' API suppliers, positioning it to become a dominant force as these companies develop, Thomson Reuters said at CPhI 2010.
Parexel opens its third office in Japan to address rising demands for clinical development and regulation services, and to supplement the capabilities of its Tokyo office which opened in 1997.
Adoption of electronic submission by regulators around the world is good news for drugmakers’ efforts to access emerging markets says industry expert Kate Wilber.
Covance has added a 40,000 sq ft biotech laboratory to its site in Indiana, US site to support its relationship with Eli Lilly and boost capacity outside Europe.
From 2005 to 2009 61 per cent of US NIH registered trials included at least one study site outside North America. Outsourcing-Pharma presents this, the 2009 downturn in US trials and other data as an interactive visualisation.
The world’s biggest drugmaker, Pfizer, is set to bulk up its collaborative research partnerships with CROs and academics in Asia to lower costs and produce more affordable drugs.
GlaxoSmithKline (GSK) has entered into two unrelated development deals by signing license agreements for Delphi Genetics’ StabyExpress for its vaccine production operations and OncoMethylome Sciences’ DNA methylation specific PCR biomarkers for its cancer...
India’s Sun Pharma has finally acquired a controlling stake in Israeli generics firm Taro Pharmaceutical Industries, significantly expanding its manufacturing capacity in North America.
Trials initiated in CEE and Russia fell 18 per cent year-on-year in 2009, ending a period of growth. Outsourcing-Pharma presents this rise and fall as an interactive visualisation.
Worrying times lie ahead for Pfizer’s advertiser, Aegis Group’s Carat, as the drug giant has decided to review its $1.3bn media account, as the firm is speculated to be slashing its outgoings.
Intelsius, formerly DGP Group, has introduced Orcatherm to address the increasing pharma industry need for temperature-controlled packaging and regulatory compliant sample transport solutions.
SOCMA CEO predicts reintroduction of rejected permanent R&D tax credit plan and urges Congress to act “sooner rather than later” to support US manufacturers.
The US FTC has given a positive advisory opinion to Rx-360’s shared audits and said the programme appears to offer “cognisable cost-saving and safety enhancing features”.
In an exclusive Q&A Mark Rohlfing, Almac’s director of Quality, updates Outsourcing-pharma on the firm’s new North American HQ, growth plans and US recruitment drive.
Indian drugmaker Cipla may invest in South Africa’s Cipla Medpro to boost manufacturing capacity and improve access to rapidly expanding African pharmaceutical markets.
Patient recruiters and national regulators must learn from each other to better understand outreach tactics and how they fit with a country’s ethics and laws.
